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Snapshot evaluation of acute and chronic heart failure in real-life in 
Turkey: A follow-up data for mortality
Introduction
Heart failure (HF) is a growing problem of the 21st century. 
A recent country-wide study demonstrated that the prevalence 
of HF in Turkey is 2.9%, affecting 1.5 million people along with 3 
million people under contiguous risk in the near future (1). There-
fore, disease burden is high. HF is a common and a growing 
problem, with rates exceeding many other countries. There are 
Objective: Heart failure (HF) is a progressive clinical syndrome. SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey. Herein, 
all-cause mortality (ACM) data during follow-up were provided.
Methods: This is a prospective outcome analysis of SELFIE-TR. Patients were classified as acute HF (AHF) versus chronic HF (CHF) and HF with 
reduced ejection fraction (HFrEF), HF with mid-range ejection fraction, and HF with preserved ejection fraction and were followed up for ACM.
Results: There were 1054 patients with a mean age of 63.3±13.3 years and with a median follow-up period of 16 (7–17) months. Survival data 
within 1 year were available in 1022 patients. Crude ACM was 19.9% for 1 year in the whole group. ACM within 1 year was 13.7% versus 32.6% 
in patients with CHF and AHF, respectively (p<0.001). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, and 
mineralocorticoid receptor antagonist were present in 70.6%, 88.2%, and 50.7%, respectively. In the whole cohort, survival curves were graded 
according to guideline-directed medical therapy (GDMT) scores ≤1 versus 2 versus 3 as 28% versus 20.2% versus 12.2%, respectively (p<0.001). 
Multivariate analysis of the whole cohort yielded age (p=0.009) and AHF (p=0.028) as independent predictors of mortality in 1 year.
Conclusion: One-year mortality is high in Turkish patients with HF compared with contemporary cohorts with AHF and CHF. Of note, GDMT score 
is influential on 1-year mortality being the most striking one on chronic HFrEF. On the other hand, in the whole cohort, age and AHF were the only 
independent predictors of death in 1 year. (Anatol J Cardiol 2020; 23: 160-8)
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several hypothetical reasons for that. It is assumed that cardio-
vascular disease begins at an earlier age, and hence, secondary 
complications including HF occur at an earlier age (2).
There are registries in different cardiovascular diseases 
including one recent registry evaluating the overall HF patient 
profile, representative of Turkey (3). With regard to the manage-
ment of HF, observational and retrospective data from tertiary 
care centers in Turkey designated that overall prescription rates 
for beta blockers (BBs) and renin–angiotensin–aldosterone sys-
tem (RAAS) blockers were acceptable; however, target dose 
was rarely achieved among patients with HF (4). In Turkey, the 
“National Heart Health Policy” has been available since 2007; 
however, complete implementation is yet to be achieved. In the 
policy paper, HF is mentioned as one of the potential growing 
future targets. In the 2025 program of the World Health Organiza-
tion, HF disease burden is mentioned in the potential targets to 
be reduced. Despite these facts, HF, hypothetically, is regarded 
as a disease of the elderly, though previous figures designate 
younger profile, and is also considered as a benign disease, and 
hence, it is not taken into consideration by many stakeholders as 
seriously as it deserves in the absence of national mortality data.
Hence, the aim of the present study was to evaluate the 
prognosis of patients with HF in a cohort representative of the 
country.
Methods
This analysis is a prospective outcome analysis of a national 
registry, named SELFIE-TR, conducted at 23 sites representing 
12 NUTS-1 regions of Turkey. The design and methodology of 
SELFIE-TR was published in the baseline characteristics pa-
per (3). Patients were classified into two as acute (AHF) versus 
chronic HF (CHF) per protocol. Patients were also classified into 
three groups as HF with reduced ejection fraction (HFrEF), HF 
with mid-range ejection fraction (HFmrEF), and HF with pre-
served ejection fraction (HFpEF) as described in the previous ar-
ticle. Chronic guideline-directed medical therapy (GDMT) score 
was calculated when data regarding the presence or absence 
of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin 
receptor blocker (ARB), BB, and mineralocorticoid receptor an-
tagonist (MRA) were available either in the discharge prescrip-
tion records of patients with AHF or in chronic medication list of 
patients with CHF. This score is used to demonstrate the relation-
ship between the use of drugs recommended by the guidelines 
and mortality. GDMT score was graded as ≤1 GDMT versus 2 
GDMT versus 3 GDMT according to the presence of these three 
groups of drugs (5-7). Patients were followed up for all-cause 
mortality (ACM), which was evaluated according to predefined 
subgroups.
This study is a project of the Heart Failure Working Group of 
the Turkish Society of Cardiology. Local Ethics Committee approv-
al was obtained (decision registration no.: B.10.4.ISM.4.06.68.49 
on July 8, 2015, protocol code no.: 288-AU/003), and also each 
center confirmed participation according to local regulations. 
To be qualified as an author in this paper, participants were in-
formed to provide both clean baseline data, exceeding the mini-
mum number of required enrollment, and 1-year outcome data. 
Participants who do not fulfill these criteria were acknowledged 
as collaborators in the previously published manuscript.
Statistical analysis
All statistics were analyzed via SPSS 23.0 software (SPSS 
Inc., Chicago, IL, USA). Categorical variables are presented as 
percentages, whereas continuous variables are presented as 
mean±standard deviation or median (interquartile range). Base-
line characteristics were classified according to predefined 
subgroups in Table 1 and evaluated via appropriate statistical 
tests including independent samples t-test for continuous vari-
ables with normal distribution, Mann–Whitney U test for con-
tinuous variables with non-normal distribution, and appropriate 
chi-square test for categorical variables. The regression analy-
sis was performed on the statistically significant parameters 
obtained from the univariate analysis, and independent predic-
tors of 1-year mortality were investigated. The effect of GDMT on 
1-year mortality in the whole cohort in patients with CHF, patients 
with chronic HFrEF, and patients with acute HFrEF was investi-
gated by using Kaplan–Meier analysis. A p value ≤0.05 was con-
sidered significant.
Results
As presented previously, there were 1054 patients with a 
mean age of 63.3±13.3 years (M/F:751/353, 71.3%/28.7%); 712 
versus 342 patients with CHF versus AHF; 801 versus 176 versus 
77 (76% vs. 16.7% vs. 7.3%) patients with HFrEF versus HFmrEF 
versus HFpEF and with a median follow-up period of 16–26 (7–17) 
months by submission of this document. The mean age of pa-
tients with CHF had been reported to be younger than that of pa-
tients with AHF (61.1±13.3 vs. 67.9±12.1 years, p<0.001), and the 
mean age of different HF phenotypes had also been significantly 
different (61.1 vs. 67.8 years, p<0.001).
ACM data within 1 year and also after 1 year were available 
in 1022 patients (32 missing, 2 signing informed consent only 
for baseline characteristics, and 30 lost to follow-up). Baseline 
characteristics of patients who died versus alive at 1-year fol-
low-up are presented in Table 1.
Crude ACM was 19.9% for 1 year (25.4% for follow-up until 26 
months) in the whole group. ACM within 1 year was 13.7% versus 
32.6% in patients with CHF and AHF, respectively (p<0.001). One-
year ACM in patients with different CHF phenotypes was similar 
and 13.7% versus 14.2% versus 11.9% in chronic HFrEF versus 
chronic HFmrEF versus chronic HFpEF, respectively (p=0.934). 
One-year ACM in patients with different AHF phenotypes was 
not significantly different from each other as 32.7% versus 28% 
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Table 1. Baseline characteristics of patients who died versus alive at 1-year follow-up
Variables Dead (n=203) Alive (n=819) P
Age (year) 69 (60-77) 61 (54-72) <0.001
Gender (male, %) 145 (71.4) 578 (71.7) 0.945
HT (n, %) 94 (46.3) 373 (45.9) 0.913
DM (n, %) 59 (29.1) 221 (27.3) 0.605
COPD (n, %) 32 (15.8) 100 (12.2) 0.177
Previous MI (n, %) 78 (38.4) 384 (46.9) 0.030
PCI (n, %) 63 (30.5) 305 (37.2) 0.075
CABG (n, %) 33 (16.3) 183 (22.3) 0.057
ICD (n, %) 28 (13.8) 147 (17.9) 0.160
CRT (n, %) 13 (3.4) 40 (4.9) 0.382
Smoking (n, %) 106 (60.2) 404 (55.2) 0.192
Heart rate (bpm) 79.3 (72-92) 77.8 (69-89) 0.014
Sinus rhythm (n, %) 109 (62.3) 488 (68) 0.264
LA size (mm) 45.7 (42-50) 45.1 (40-50) 0.027
sPAP (mm Hg) 45.7 (35-56) 40.8 (30-50) <0.001
EF (%) 30.5 (25-40) 30.3 (25-40) 0.135
LVEDD (mm) 59.4 (52-66) 58.2 (52-64) 0.324
ACEI (n, %) 102 (50) 461 (53.3) 0.672
ARB (n, %) 27 (13.4) 127 (15.5) 0.546
BB (n, %) 165 (81.4) 731(89.3) 0.500
MRA (n, %) 78 (38.4) 431 (52.6) 0.005
Ivabradine (n, %) 27 (13.4) 129 (15.7) 0.526
Digoxin (n, %) 20 (9.9) 91 (11.1) 0.629
Median GDMT score  1 (1-3) 2 (2-3) <0.001
Fully accomplished GDMT (n, %) 42 (20.5) 289 (35.3) 0.002
Type of HF (%)
 HFrEF 155 (76.4) 625 (76.3) 0.916
 HFmrEF 31 (15.3) 139 (17)
 HFpEF 17 (8.4) 55(6.7)
Acute HF (n, %) 109/203 (53.7%) 227/819 (27.5%) <0.001
Hb (g/dL) 12.5 (11-14) 13.2 (11.7-14.6) <0.001
Htc (%) 38.7 (33.9-42.9) 40.2 (36.3-44.3) 0.001
WBC (103/µL) 8.34 (6.81-10.97) 7.94 (6.59-9.49) 0.006
BNP (pg/mL) 54.6 (24.9-85.1) 46.25 (29.25-80.50) 0.909
NTproBNP (pg/mL) 2495 (368-4850) 1402.50 (552.25-4165) 0.631
Na (mmol/L) 137 (133-140) 138 (136-140) <0.001
K (mmol/L) 4.46 (4.00-4.89) 4.47 (4.08-4.89) 0.658
Creatinine (mg/dL) 1.29 (0.93-1.72) 1.02 (0.82-1.30) <0.001
Glucose (mg/dL) 115 (94-16) 111 (96-146) 0.555
ALT (U/L) 20 (13-40) 19 (14-29) 0.615
Total cholesterol (mg/dL) 155 (124-185) 169 (134-201) 0.041
TG (mg/dL) 92 (71-129) 123 (84-182) <0.001
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versus 40% in acute HFrEF versus acute HFmrEF versus acute 
HFpEF, respectively, though there were numerical differences 
(p=0.541).
Information regarding chronic medications was available 
in 769 patients and was lacking in 269 patients by the time of 
preparation of this document. ACE inhibitor or ARB was present 
in 70.6% (71.5% vs. 68.4% in CHF vs. AHF, p=387), BB was present 
in 88.2% (89.3% vs. 85.5% in CHF vs. AHF, p=0.141), and MRA was 
present in 50.7% (54.5% vs. 41.7% in CHF vs. AHF, p=0.001) of all 
patients. ACEI/ARB, BB, and MRA were present in 74.7%, 89.7%, 
and 60.9% of patients with chronic HFrEF phenotypes.
Multivariate analysis of the whole cohort including patients 
with HFrEF, HFmrEF, and HFpEF together yielded age (p=0.009) 
and having AHF (p=0.028) as independent predictors of mortality 
in 1 year (Table 2).
In the whole cohort, survival curves were graded according 
to GDMT scores ≤1 versus 2 versus 3 as 28% versus 20.2% ver-
sus 12.2%, respectively (p<0.001, Fig. 1). In patients with CHF with 
available mortality and available GDMT score (n=520), 1-year mor-
tality was 14.9% versus 12.3% versus 5.6% for GDMT scores ≤1 
versus 2 versus 3, respectively (p=0.002 for Kaplan–Meier, Fig. 2).
In patients with chronic HFrEF, 1-year mortality was 14.3% 
versus 14% versus 5.8% for GDMT scores ≤1 versus 2 versus 
Table 1. Cont.
Variables Dead (n=203) Alive (n=819) P
HDL (mg/dL) 35 (29-42) 38 (30-45) 0.127
LDL (mg/dL) 100 (76-121) 105 (83-133) 0.233
HT - hypertension; DM - diabetes mellitus; COPD - chronic obstructive pulmonary disease; MI - myocardial infarction; PCI - percutaneous coronary intervention; CABG - coronary 
artery bypass grafting; ICD - implantable cardioverter defibrillator; CRT - cardiac resynchronization therapy; LA - left atrium; sPAP - systolic pulmonary artery pressure; EF - 
ejection fraction; LVEDD - left ventricular end diastolic diameter; ACEI - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker; BB - beta blocker; MRA 
- mineralocorticoid receptor antagonist; GDMT - guideline-directed medical therapy; HF - heart failure; HFrEF - heart failure with reduced ejection fraction; HFmrEF - heart failure 
with mid-range ejection fraction; HFpEF - heart failure with preserved ejection fraction; Hb - hemoglobin; Htc - hematocrit; WBC - white blood cell; Plt - platelet; BNP - brain 
natriuretic peptide; NTproBNP - N-terminal probrain natriuretic peptide; Na - sodium; K - potassium; AST - aspartate aminotransferase; ALT - alanine aminotransferase; TG - 
triglycerides; HDL - high-density lipoprotein; LDL - low-density lipoprotein
Table 2. Multivariate analysis for mortality in 1 year
Variables Univariate OR, 95% CI P Multivariate OR, 95% CI P
Age 1.03 (1.01-1.04) <0.001 1.06 (1.01-1.12) 0.009
Hb 0.83 (0.77-0.91) <0.001 1.21 (0.88-1.68) 0.227
WBC 1.03 (0.99-1.06) 0.11 1.09 (0.88-1.34) 0.411
Na 0.93 (0.90-0.96) <0.001 0.92 (0.82-1.04) 0.198
Creatinine 1.01 (0.97-1.05) <0.001 1.51 (0.64-3.55) 0.336
TG 0.99 (0.98-0.99) 0.003 0.99 (0.98-1.00) 0.089
Previous MI 1.41 (1.03-1.93) 0.030 1.93 (0.73-5.05) 0.181
Acute HF 3.06 (2.23-4.19) <0.001 3.21 (1.13-9.09) 0.028
LA size 1.02 (1.01-1.05) 0.027 0.99 (0.92-1.08) 0.973
sPAP 1.02 (1.01-1.04) <0.001 0.99 (0.92-1.02) 0.667
Heart rate  1.01 (1.00-1.02) 0.014 1.01 (0.98-1.04) 0.439
Median GDMT score 0.59 (0.45-0.78) <0.001 1.80 (0.88-3.68) 0.102
Hb - hemoglobin; Na - sodium; WBC - white blood cell; TG - triglycerides; MI - myocardial infarction; HF - heart failure; LA - left atrium; sPAP - systolic pulmonary artery pressure; 
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Figure 1. Whole cohort survival curves according to GDMT score
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3, respectively (p=0.011, Fig. 3). In patients with chronic HFmrEF, 
there was a nonsignificant graded decrease of ACM by increas-
ing GDMT scores (15.6% vs. 11.4% vs. 4.8% for GDMT scores ≤1 
vs. 2 vs. 3, respectively, p=0.475).
In patients with AHF with available mortality and available 
GDMT score (n=221), 1-year ACM was 37.7% versus 20.9% ver-
sus 24% for GDMT scores ≤1 versus 2 versus 3, respectively 
(p=0.053). Furthermore, in patients with acute HFrEF phenotype 
and with available GDMT score (n=170), 1-year ACM was 44.2% 
versus 19.8% versus 23.9% for GDMT scores ≤1 versus 2 versus 
3, respectively (p=0.024, Fig. 4).
Discussion
In this analysis, evaluating the data from SELFIE-TR registry, 
the mortality rates, mortality predictors, GDMT utilization, and 
associated mortality rates according to GDMT score were in-
vestigated. The main results of our study could be summarized 
as follows:
1. Patients with HF in Turkey were relatively younger than pa-
tients with HF in the other contemporary cohorts, and the 
mortality rate was high despite young age. Studies have dem-
onstrated that the average age of patients with HF is different 
between countries (8-12). In the ESC-HF pilot study, the mean 
age of patients with CHF was 67 years, similar to this study, 
whereas the mean age of patients with AHF was 70 years, 
and it was 61 years in the SELFIE-TR study (13). ACM rate 
was 19.9% in all cohort.
2. GDMT including ACEI or ARB plus BB plus MRA, traditionally 
known to improve the prognosis of HFrEF, yielded graded sur-
vival curves in the whole cohort (in the analysis including all 
phenotypes). Of note, in further subgroup analysis, fully ad-
ministered GDMT significantly decreased mortality rates in 
patients with HFrEF down to the numerical levels, expressed 
in the contemporary registries (14).
3. In this analysis, when the whole cohort, i.e., all phenotypes 
of HF, was considered, age and having AHF were shown to be 
independent predictors of 1-year mortality.
HF is a clinical syndrome secondary to incapabilities of one 
or both ventricles to fill with or eject blood. Significant improve-
ments were obtained in the diagnosis and treatment of some HF 
phenotypes along with improved technology. The goals of treat-
ment in patients with HF should be based on relieving symptoms 
and findings, preventing recurrent hospitalizations, and improv-
ing survival.
Traditionally, the left ventricular ejection fraction is used in 
the definition of HF. In the recent European Society of Cardiol-
ogy (ESC) guidelines (15), HF was classified into three pheno-
typic groups based on EF as follows: 1) patients with EF >50% 
as Group HFpEF, 2) patients with EF <40% as Group HFrEF, and 3) 
patients with EF 40%–49% as Group HFmrEF. This classification 
might be important since there are different underlying etiolo-
gies, demographic characteristics, comorbidities, and response 
to treatments. HFrEF is the most commonly studied subgroup of 
HF. There are treatments proven to be effective in this pheno-
type. ACEIs/ARBs (or angiotensin receptor neprilysin inhibitor 
(ARNI) recently), BBs, and MRAs, whose effects were estab-
lished repeatedly in observational and randomized controlled 
studies (16-33), are definitely recommended as evidence-based 
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treatments by the ESC (15) and American Heart Association/
American College of Cardiology Foundation (AHA/ACC3) (34, 35) 
yielding a reduction in mortality and morbidity, and hence, are 
collectively called GDMT. Therefore, GDMT including ACEIs/
ARBs (or ARNI according to most recent guidelines), BBs, and 
MRAs has become a cornerstone therapy for the prevention of 
disease progression in HFrEF. Since these drugs exert their ef-
fects on the RAAS and the sympathetic nervous system through 
different pathways, combination appears to exert synergistic 
benefits. It has been shown that BBs and MRAs initiated in ad-
dition to ACEI/ARB not only caused a reduction in hospitaliza-
tions but also yielded additional mortality benefits in patients 
(36). Hence, the drugs should be initiated as soon as possible, 
and they should be titrated up to the highest dose according to 
patient tolerability.
Since the whole patient population included patients from 
each of three HF phenotypes, age and having AHF were found 
to be independently associated with mortality in the multivari-
ate regression analysis consistent with the literature data (23, 
37-42). Of note, GDMT or aforementioned drugs were not inde-
pendent predictors of mortality in 1 year. The absence of the 
independent prognostic role of GDMT may also be consistent 
with the literature since no pharmacological agent specifically 
yielded mortality benefit in HFpEF and HFmrEF phenotypes con-
trary to HFrEF. Relative inefficiency of components of GDMT in 
HFpEF and HFmrEF phenotypes might have reduced the statis-
tical power of GDMT–HFrEF relationship relative to the whole 
group. It should also be kept in mind that the study did not 
consider de novo GDMT, rather made a snapshot prevalence 
of GDMT; hence, incident GDMT might have yielded positive 
outcomes (43-50). Furthermore, the duration of GDMT might not 
be sufficient to yield prognostic benefit in 1 year, even in inci-
dent GDMT cases, and might have already yielded positive out-
comes in prevalent GDMT cases (particularly those enrolled as 
patients with CHF were those who survived via already initiated 
GDMT). Last but not the least, survival benefit of ACEIs/ARBs, 
BBs, and MRAs usually is known to appear after 1 year in the 
majority of clinical trials.
On the other hand, overlapping curves of GDMT 1 and GDMT 
2 in Kaplan–Meier analysis of patients with HFrEF might be due 
to small patient population, not on BBs among patients with 
chronic HFrEF in the cohort. Marked superiority of GDMT 3 over 
GDMT 1 and 2 can support the notion that triple blockade includ-
ing the sympathetic nervous system, angiotensin pathway, and 
aldosterone pathway is compared with dual blockade. It was 
shown that blocking all of these mechanisms was superior to 
other dual combinations particularly in HFrEF (36, 51). This find-
ing strongly supports the paradigm that triple therapy should not 
be delayed in suitable patients with chronic HFrEF.
The use of GDMT in patients hospitalized due to AHF is also 
worth mentioning herein. Prior to hospital discharge, both the 
American and European guidelines recommend to initiate these 
therapies, which are known to improve survival (15, 34, 35, 52, 
53). Hence, it has been recommended to continue and/or initi-
ate GDMT during AHF episode (preferably just after the initial 
stabilization) and definitely before discharge (54-58). In our study, 
it was shown that as GDMT score increased, 1-year mortality 
rate decreased not only in chronic HFrEF but also in patients with 
acute HFrEF. However, different from GDMT–mortality relation-
ship in chronic HFrEF, double and triple GDMT (i.e., GDMT scores 
2 and 3) were statistically better than GDMT 1, but triple GDMT 
was not better than dual GDMT in the first year outcome analy-
sis. This issue might be driven by continuing prescription prac-
tice that MRAs are reserved for relatively more advanced stages 
of HF, particularly after decompensation, and hence potentially 
yielding poorer prognosis despite triple GDMT (after the addition 
of MRA) in the first year.
In our study, 1-year mortality rates of patients with AHF 
were higher than those of patients with CHF. Our finding was 
confirmatory to the findings of OPTIMIZE-HF (56), ADHERE (40), 
EHFS II (41), and EUROHEART (42), in which mortality rates of 
patients with AHF were reported to be higher than those of pa-
tients with CHF.
In mortality analysis according to phenotypes, while there 
were numerical differences, no statistically significant differ-
ence was observed in 1-year mortality. There is divergence of 
survival analysis in the literature according to HF phenotypes. 
In a meta-analysis including 31 studies (Meta-analysis Global 
Group in Chronic Heart Failure) (38), HFrEF and HFpEF were 
compared in patients with CHF, and the mortality of patients with 
HFrEF was higher. In the ESC Heart Failure registry (59), three 
phenotypes of CHF were compared, and ACM rates in patients 
with HFrEF versus HFmrEF versus HFpEF were found to be 8.8% 
versus 7.6% versus 6.3%, respectively, with a statistically signifi-
cant difference. Higher mortality rates were noted in our cohort 
as 13.7% versus 14.2% versus 11.9% in respective phenotypes. 
In the subgroup analysis of the CHARM study, ACM rates in pa-
tients with HFrEF versus HFmrEF versus HFpEF were found to be 
10.7% versus 5.4% versus 5.7%, respectively (60). These differ-
ences can be explained by geographical difference, different de-
mographic characteristics of the patients, and lower GDMT use 
or even the dose of GDMT. Of note, fully accomplished GDMT 
resulted in mortality rates, compatible with contemporary reg-
istries. Similar to the ESC Heart Failure registry, it was observed 
that the demographic data of the ESC pilot study differed with our 
SELFIE-TR study (13). These differences and their interpretations 
are mentioned in our first article where baseline characteristics 
are presented (3).
GDMT rates vary according to the development level of the 
countries and the socioeconomic level of the patients (61, 62). In 
a US study, the GDMT score was 2.31 and increased to 2.74 in 
the follow-up (6).
One-year mortality rates in HFrEF versus HFmrEF versus 
HFpEF AHF phenotypes were 32.7% versus 28% versus 40%, re-
spectively. These rates are comparable to those by Coles et al. 
(63) reported mortality data in patients with AHF intermittently 
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from 1994 to 2004. According to these temporal records, 1-year 
mortalities of acutely decompensated HFrEF, HFmrEF, and HFpEF 
in 1995 and 2004 were 40.4% and 32.6%, 25.4% and 28.7%, and 
35% and 29.1%, respectively. Hence, improvement in mortality 
trends is noted in AHF, similar to CHF.
Study limitations
There are several limitations worthwhile mentioning. First, 
the snapshot nature of the present study was a significant lim-
iting factor since temporal trends in GDMT utilization and risk 
factor modification could potentially have significantly impacted 
outcomes. Second, the number of patients with HFpEF in the co-
hort was limited (and also HFmrEF to some extent), and hence, 
these findings should be interpreted with a word of caution. Third, 
the doses of GDMT including ACEIs or ARBs and BBs were not 
separately recorded in the case report forms; hence, the doses 
of GDMTs were unknown until the conduct of this analysis. Of 
note, high doses of some GDMTs were previously shown to im-
pact outcomes in HFrEF population. On the other hand, during 
the plan and conduct of the registry, phenotypic classifications 
had to be based on the existing 2013 ACC/AHA HF guidelines 
of that time. Such phenotypic definitions were updated during 
the data analysis period for the sake of uniformity of definitions, 
particularly HF with borderline ejection fraction was updated 
as HFmrEF. Although, many previous publications utilized these 
assumptions and transitional nomenclature updates, this might 
potentially end up with some deficits in the interpretation of the 
results. Moreover, adherence and compliance to GDMT remain 
as important confounders in the study since those issues were 
not taken into consideration in this analysis.
Conclusion
Overall, in this country-representative snapshot, patients 
with HF in Turkey were relatively younger than those in many 
other cohorts, particularly patients with chronic HFrEF. One-year 
mortality in Turkish patients with HF was high despite young age, 
and this might potentially be related to lower rates of GDMT. 
However, fully accomplished GDMT as indicated by GDMT score 
appears to decrease ACM in all HF phenotypes in a year, but dra-
matically in patients with HFrEF, and hence appears to lower high 
mortality rate to average numbers of contemporary HF registries. 
Age and having AHF remained as the independent predictors of 
mortality in 1 year irrespective of HF phenotype.
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